ArticleFrontiers in oncology2026
Association between amide proton transfer-weighted imaging biomarkers and Gleason score in prostate cancer: a study on differential diagnosis from benign prostatic hyperplasia.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population.Medical oncology (Northwood, London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: The non-invasive differentiation of prostate cancer (PCa) from benign prostatic hyperplasia (BPH) and the accurate assessment of tumor aggressiveness remain critical clinical challenges. This study aimed to evaluate the diagnostic performance of amide proton transfer-weighted (APTw) MRI and, specifically, to determine its incremental value over the standard Prostate Imaging-Reporting and Data System (PI-RADS v2.1) and serum PSA. Methods: In this retrospective study, 160 patients (86 PCa, 74 BPH) underwent 3.0T multi-parametric MRI, including APTw imaging. Quantitative APTw values were compared with Apparent Diffusion Coefficient (ADC) values and PI-RADS v2.1 scores. Receiver operating characteristic (ROC) analysis was employed to evaluate the diagnostic performance of individual parameters and combined models. Subgroup analyses were performed for lesions in the Transition Zone (TZ) and patients in the PSA "gray zone" (4-10 ng/mL). Additionally, the correlation between APTw values and the Gleason Score (GS) was assessed. Results: APTw values were significantly higher in the PCa group compared to the BPH group (2.1% ± 0.5% vs. 1.3% ± 0.6%, p < 0.001). While PI-RADS v2.1 alone showed high diagnostic efficacy (AUC = 0.875), the combined model (APTw + PI-RADS v2.1) achieved the highest accuracy with an AUC of 0.915, significantly outperforming PI-RADS alone (p < 0.05). In the challenging PSA "gray zone", APTw imaging maintained robust diagnostic performance (AUC = 0.80), significantly outperforming serum PSA (AUC = 0.75). Furthermore, a significant positive correlation was observed between APTw values and GS (Spearman's ρ = 0.407, p < 0.001), and APTw successfully differentiated high-risk (GS ≥ 8) from low- and intermediate-risk PCa (AUC = 0.715). Conclusion: APTw imaging correlates with tumor aggressiveness and provides excellent diagnostic performance for differentiating PCa from BPH. Crucially, it offers incremental diagnostic value to the standard PI-RADS v2.1 assessment and demonstrates robust utility in challenging clinical scenarios, such as the PSA gray zone, thereby serving as a valuable non-invasive biomarker for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.